Verge Genomics to Present at 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022
SAN FRANCISCO--(BUSINESS WIRE)-- Verge Genomics, a tech-enabled drug discovery company pioneering the use of artificial intelligence (AI) and human data to develop new drugs will present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11th at 4:30 p.m. EST. Co-founder and CEO Alice Zhang will provide an overview of Verge and recent pipeline and corporate milestones.
Ms. Zhang’s presentation will be available as a live webcast through the J.P. Morgan Healthcare Conference portal and an archived recording will be made available after the event.
Last December, Verge Genomics announced that it closed an oversubscribed $98 million equity financing. Funding from the Series B will be used to exponentially grow the number of preclinical and clinical programs in Verge’s pipeline and advance its lead programs through clinical testing. Verge will also continue to expand its proprietary technology to transform the drug discovery process, including translational medicine and clinical development. Additionally, in July 2021, the company announced a $706 million partnership with Eli Lilly and Company to develop new treatments for amyotrophic lateral sclerosis (ALS) using Verge’s platform.
About Verge Genomics
Verge uses AI and human data to develop better drugs faster for large unmet diseases. Verge has built an end-to-end drug discovery and development platform, featuring one of the field’s largest and most comprehensive proprietary patient genomics datasets in neuroscience. Verge applies machine learning to reveal new targets from human datasets and develops drugs with greater probabilities of success using its human-centric biology and chemistry platforms.
Verge is the first AI-enabled drug discovery company to internally develop a clinical candidate from a novel target discovered from its platform. Verge has further demonstrated the power of its platform by delivering a broad preclinical and discovery pipeline spanning diverse therapeutic areas, with its first program, a PIKfyve inhibitor for the treatment of ALS, expected to enter the clinic in 2022. The company is led by experienced drug developers and computational biologists with a shared belief that technology has created a new opportunity to deliver life-changing medicines more efficiently.
Source: Verge Genomics